Beerse and Olen are the sites of pharmaceutical production of medicines. The active substances are processed into medicines here. The production plant in Beerse is a ‘high-volume plant’ and a ‘center of excellence’ for certain technologies, such as products in liquid and semi-solid form, transdermal products and sterile products.

The production focuses on Quality by Design and replaces the traditional development strategy with systematic methods which are supported by statistical and risk analyses. Not only are safe and efficacious products produced here, but so is a process that is robust, scaleable and cost-efficient. 

At the moment, a pilot project is in progress in Beerse with a view to implement complete automation, which should link everything in terms of production, administration, logistics, maintenance, etc. 

Supply_Chain_Beerse_DL06 (1).jpg
Supply_Chain_Beerse_DL52.jpg

There is also a project that should make the quality control superfluous at the end of the process. This is because we want to achieve quality control during every step of the production process.

Janssen uses several strategic instruments in this production process. This is primarily because these techniques are good tools for developing an improvement culture, which is of crucial importance for controlling costs in the current economic climate. In this context, Janssen pays due attention to Lean Manufacturing. The major aspect of these techniques is that they encourage staff to think in a more process-oriented way, even across the boundaries of the different departments. 

Durabilité
Économique

Janssen believes that strong corporate results, correct policies and focused activities pave the way towards economic sustainability. 

Janssen must constantly reinvent itself in order to cope with the structural and economic changes that affect its environment. This is why Janssen is committed to build partnerships within an open innovation model, and to the continuous alignment of its cost-competitiveness by only developing medicines with a high therapeutic added value. 

For Janssen this means specifically: being focused and a leader in research & development, and being efficient and progressive in terms of production with the aim of bringing new therapeutic solutions to patients quicker and at less expense, and implementing a growth strategy to ensure our continued investment in all these areas.